Immunomedics

Acquired

Next-generation ADC therapies for hard-to-treat cancers.

Immunomedics is a biotech company in Morris Plains, United States, founded in 2004. It has raised $459.0M across 1 round, most recently a $459.0M Private Equity in May 2020.

Employees
201–500
Founded
2004
Business Model
B2B
Total Funding
$459.0M
Last Round
$459.0M Private EquityMay 2020
Rounds
1
Acquired by
GileadOct 2020 · $21.0B

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 1 investor for this company. to use credits for reveals, or explore the API.

About

Immunomedics was a clinical-stage biopharmaceutical company pioneering next-generation antibody-drug conjugate (ADC) technology for the targeted treatment of cancer, including triple-negative breast cancer and other solid tumors. Its lead drug, Trodelvy (sacituzumab govitecan), received FDA approval before the company was acquired by Gilead Sciences for $21 billion in 2020.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionAcquisition by Gilead SciencesSep 2020

1 more funding event

  • Private Equity2020

Funding: Private Equity. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

  • CRM & Sales ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech
Corporate RoundTotal funding$2.8BJan 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech
Series CTotal funding$955.0MSep 2024

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Immunomedics on Indexed.vc
<a href="https://indexed.vc/companies/immunomedics"><img src="https://indexed.vc/api/badge/company/immunomedics" alt="Immunomedics on Indexed.vc" width="260" height="76" /></a>